About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Colon cancer patients benefit from Hepatic Arterial Infusion Therapy

by Medindia Content Team on February 28, 2006 at 11:16 AM
Font : A-A+

Colon cancer patients benefit from Hepatic Arterial Infusion Therapy

A new study conducted by Nancy E. Kemeny, MD, an Attending Physician in the Department of Medicine at Memorial Sloan-Kettering Cancer Center said that patients whose colorectal cancer has spread to the liver fared better by receiving hepatic arterial infusion (HAI). In this technique chemotherapy was administered directly to the liver through a pump in the abdomen. It was found that the patients on the HAI therapy lived longer and had better quality of life than those receiving the traditional, intravenous chemotherapy. The results of the study were published in the Journal of Clinical Oncology.

This study demonstrated the effectiveness of the hepatic arterial infusion therapy. It showed that it extended the survival and improved the quality of life in patients with colorectal cancer that has spread to the liver. These findings are very important because statistics show that cancer metastasis to the liver occurs in 60 % of patients with metastatic colorectal cancer. This discovery will also reduce the number of deaths due to liver tumors.

Advertisement

The study was conducted by researchers from the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. The participants consisted of 135 patients who received either HAI or systemic chemotherapy. Prior to this all of the patients are needed to undergo surgical removal of their primary tumors in the colon. In case of patients receiving HAI then underwent an additional surgical procedure to have chemotherapy pump inserted into their abdomen.

Researchers found that patients receiving HAI lived longer (median survival rate of 24 months) than those receiving systemic chemotherapy. They also had better response rates (47 %) and longer time to disease progression in the liver (9.8 months).
Advertisement

On the other hand patients receiving systemic chemotherapy experienced various side effects such as diarrhea, decreased white blood cell counts, and hair loss. However, patients on the HAI regimen experienced mild toxicity to the liver.

In case of both the regimes women fared better than men, with median survival in the HAI group of 29.4 and 20.1 months for women and men, respectively, and in the systemic group it was 22.0 and 18.3 months.

This research was initiated in the year 1996, before the novel chemotherapy drugs such as irinotecan and oxaliplatin were available. In the study the patients received fluorouracil and leucovorin. Dr. Kemeny said that future studies are underway using HAI therapy in combination with newer drugs.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Colo-rectal cancer - Management Colorectal Cancer Reiki and Pranic Healing Cancer Facts Cancer Colon Crohns Disease Diverticulosis and Diverticulitis Colon Polyps 

Most Popular on Medindia

Sinopril (2mg) (Lacidipine) Noscaphene (Noscapine) Turmeric Powder - Health Benefits, Uses & Side Effects Sanatogen Drug - Food Interactions Pregnancy Confirmation Calculator Accident and Trauma Care Diaphragmatic Hernia Blood Donation - Recipients Blood - Sugar Chart
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use